Physician profile
Stanley Alan Plotkin
NPI 1184068462
$146,942.61
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $7,516 · 2021: $57K · 2022: $14K · 2023: $27K · 2024: $5,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,080 · Travel and Lodging: $997 · Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,490.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,080.00 |
| Travel and Lodging | $996.98 |
| Food and Beverage | $292.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $75,367.44 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $36,595.61 | 2019-2024 | Pneumovax 23 |
| Janssen Scientific Affairs, LLC | $13,000.00 | 2020-2022 | |
| Pfizer INC. | $9,582.26 | 2019-2024 | |
| Seqirus USA INC | $9,344.00 | 2021-2022 | |
| Biontech Se | $1,500.00 | 2023 | |
| Glaxosmithkline, LLC. | $1,016.30 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $537.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Plotkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.